AstraZeneca and Daiichi Sankyo sign $6.9bn cancer drug development deal

Trastuzumab deruxtecan is an antibody-drug conjugate (ADC) designed to target and deliver chemotherapy within cancer cells. Credit: © AstraZeneca.



  • AstraZeneca, Daiichi Sankyo sign $6.9bn cancer drug development deal